![]() |
市場調査レポート
商品コード
1661631
神経血管血栓除去装置の世界市場の評価:タイプ別、用途別、エンドユーザー別、地域別、機会および予測、2018~2032年Global Neurovascular Thrombectomy Devices Market Assessment, By Type, By Application, By End User, By Geographies Opportunities, and Forecast, 2018-2032F |
||||||
カスタマイズ可能
|
神経血管血栓除去装置の世界市場の評価:タイプ別、用途別、エンドユーザー別、地域別、機会および予測、2018~2032年 |
出版日: 2025年02月25日
発行: Market Xcel - Markets and Data
ページ情報: 英文 235 Pages
納期: 3~5営業日
|
神経血管血栓除去装置の世界市場は2024年に29億5,000万米ドルと推定され、2025年から2032年の予測期間にはCAGR 6.72%で成長すると予測されています。低侵襲手技の増加、患者集団における脳卒中発症率の増加、技術的ブレークスルー、償還政策、新興国政府による医療費支出が増加していることなどが、市場拡大を促進する要因となっています。中国やインドなどのアジア太平洋諸国は、2025年から2032年にかけて新たな収益を生み出す市場になると予測されています。
主要企業による継続的な製品開発と、製造施設、研究開発施設、流通網の設立を通じて新興国でのプレゼンスを拡大する主要市場企業は、予測期間中に血栓除去装置のさらなる成長を促進すると予想されます。WHOが発表した報告書によると、神経血管血栓除去術は先進国と新興国の両方で術後の患者転帰の改善を示しており、血栓除去術は先進国と新興国の両方で急成長しています。血栓除去術治療を受ける大血管閉塞またはLVO脳卒中患者の割合は国によって異なるが、そのほとんどは15%未満にとどまっています。
すべてのセグメントは、対象となるすべての地域と国で提供されます。
上記の企業は市場シェアに基づいて注文を保留しておらず、調査作業中に入手可能な情報に応じて変更される可能性があります。
The Global Neurovascular Thrombectomy Devices Market was estimated at 2.95 billion in 2024, and is projected to grow at a CAGR of 6.72% for the forecast period between 2025 and 2032. Increasing number of minimally invasive procedures, increasing incidence of stroke in patient population, technological breakthroughs, reimbursement policies, and rising healthcare expenditure by governments across emerging economies are some of the factors driving market expansion. Asia-Pacific nations such as China and India are predicted to emerge as new revenue-generating markets between 2025 and 2032.
Ongoing product developments by leading companies and key market players expanding their presence in emerging countries through the establishment of manufacturing facilities, research and development facilities, and distribution networks are expected to drive further growth of thrombectomy devices during the forecast period. As per reports published by WHO, neurovascular thrombectomy have shown improved patient outcomes post-surgery in developed and emerging countries, thrombectomy operations have grown rapidly in both established and emerging countries. The percentage of large vessel occlusion or LVO stroke patients undergoing thrombectomy treatments varies by country, however most of them stay below 15%.
Mergers and Acquisitions Support Market Expansion
Mergers and acquisitions are significant a driver for the global neurovascular thrombectomy devices market. They enable companies to expand their product portfolios by acquiring advanced technologies, thus catering to a wider range of medical needs. Mergers and acquisitions also facilitate entry into new geographic markets, increasing patient reach, and thus market share. Additionally, combining resources through mergers and acquisitions enhances research and development capabilities, leading to the innovation of more effective thrombectomy devices. Strategic partnerships formed through mergers and acquisitions improve supply chain efficiency and distribution networks, bolstering overall operational effectiveness.
For instance, in January 2025, Stryker Corporation announced a definitive agreement to acquire Inari Medical, Inc. This acquisition is expected to enhance Stryker's capabilities in treating vascular diseases, particularly in the context of thrombectomy procedures. This strategic move is allowing Stryker to broaden its product portfolio and address a wider range of vascular conditions, enhancing its market presence.
Stent Retriever is Dominating the Global Neurovascular Thrombectomy Devices Market
In 2022, the stent retrievers accounted for majority share the overall mechanical thrombectomy devices market, owing to increased reimbursement, increased public-private investments in product development & commercialization, and increased patient emphasis on minimally invasive therapeutic procedures.
North America is Expected to Hold a Significant Share during the Forecast Period
Over the projected period, North America is likely to have a sizable market share. The increasing frequency of acute ischemic strokes, increased research and development, regular product launches, and rising strategic initiatives by leading market players are the fundamental driving drivers for the North American neurovascular thrombectomy devices market.
Due to high frequency of stroke in the United States, the North American is expected to hold a substantial proportion of the market over the study period. According to the Centers for Disease Control and Prevention (CDC) report published in April 2022, more than 795,000 people in the United States experience a stroke each year and ischemic strokes account for approximately 87% of all reported strokes.
Impact of COVID-19 on the Global Neurovascular Thrombectomy Devices Market
COVID-19 has had a significant impact on the healthcare industry, including the neurovascular thrombectomy devices market. On one hand, there has been an increase in demand for these devices due to the higher incidence of stroke in COVID-19 patients. COVID-19 is known to cause blood clotting, which can increase the risk of stroke in patients. On the other hand, the pandemic disrupted supply chain and led to manufacturing and distribution challenges for neurovascular thrombectomy device manufacturers. Some manufacturers had to delay or halt production due to workforce shortages, supply chain disruptions, and other factors. This led to a shortage of neurovascular thrombectomy devices in some regions, which affected patient's access to these devices.
Impact of Russia-Ukraine War on the Global Neurovascular Thrombectomy Devices Market
The war between Russia and Ukraine had an indirect negative impact on the neurovascular thrombectomy market on a global scale. Geopolitical tensions and conflicts can have broader impacts on the global economy and neurovascular thrombectomy market due to trade disruptions, supply chain interruptions and economic sanctions imposed by United States and European countries on Russia.
Key Players Landscape and Outlook
Some of the leading companies in the Neurovascular Thrombectomy Devices market are Johnson & Johnson Medical Ltd, Medtronic Plc, Wallaby Medical Inc, Terumo Corp, Stryker Corp, Imperative Care Inc, Penumbra Inc, Balt SAS, and Acandis GmbH & Co KG. Medtronic Plc.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work